Overview of Anafranil SR

Property	Description
Active Ingredient	Clomipramine Hydrochloride
Form	Sustained-Release Tablet (SR)
Pharmacological Class	Tricyclic Antidepressant (TCA)
Common Use	Neurotransmitter Modulation / Mood Stabilization
Origin	Synthetic, Dibenzazepine derivative

What Type of Medicine is Anafranil SR?

Anafranil SR is a specific formulation of the prescription-only, psychoactive medication defined by its active component, Clomipramine Hydrochloride, and is precisely classified within the pharmaceutical category of Tricyclic Antidepressants (TCAs).

The active substance, Clomipramine, is a synthetic compound and a Dibenzazepine derivative, which dictates its specific chemical structure and broad mode of action among Central Nervous System (CNS) agents. Clomipramine acts on the brain's chemical messengers, serotonin and norepinephrine, to exert its therapeutic effects. Its classification as a TCA reflects its profile as an agent used in stabilizing emotional and cognitive function.

Understanding the Sustained-Release (SR) Formulation

The designation SR stands for Sustained-Release, meaning Anafranil SR is an Oral dosage form formulated as a Modified-Release Tablet designed to deliver the medication slowly and consistently over an extended period after ingestion.

This specific, branded formulation ensures controlled absorption of Clomipramine Hydrochloride into the bloodstream, preventing the high concentration peaks and subsequent rapid declines that characterize immediate-release versions. Modified-release formulations are designed to help maintain steady plasma concentrations, which supports consistent therapeutic stability. This stable release profile contributes to predictable and steady drug levels, which can be advantageous in long-term therapeutic management where uniform effect is prioritized.

General Purpose and Action of Clomipramine Hydrochloride

The core purpose of Clomipramine Hydrochloride is its function as a neurotransmitter modulator, aiming to restore the chemical balance of specific messengers in the brain.

This fundamental mechanism involves the inhibition of the reuptake of these chemical messengers, thereby increasing their availability and enhancing communication between nerve cells. By rebalancing the levels of these critical chemicals, the medicine supports the regulation of mood and thought processes in the Central Nervous System, ultimately serving the general therapeutic goal of promoting emotional stability and regulating distressing mental states.

Regulatory References

Modified Release Guideline

What side effects are possible with Anafranil SR?

Possible side effects and safety information

The safety profile for Anafranil SR (Clomipramine Hydrochloride) is defined by adverse reactions, frequency classifications, and systemic effects documented in government regulatory sources. These official documents categorize effects by their estimated rate of occurrence and the organ systems involved, without offering clinical advice.

Frequency-Classified Adverse Reactions

The official labeling classifies many effects as Very Common (ge 1/10), particularly those related to anticholinergic activity and the Central Nervous System (CNS). These include dry mouth, constipation, dizziness, somnolence (drowsiness), tremor, and sweating. Reactions classified as Common (ge 1/100 to < 1/10) include nausea, vomiting, weight gain, postural hypotension, sinus tachycardia, and anxiety.

System-Organ Classes and Serious Adverse Reactions

Adverse effects are formally grouped under classes such as Nervous System Disorders (e.g., tremor, myoclonus), Gastrointestinal Disorders (e.g., dry mouth, constipation), and Cardiac Disorders (e.g., sinus tachycardia). Serious adverse reactions explicitly documented in regulatory sources include the potential for Seizures (convulsions), Serious Cardiac Arrhythmias, and Serotonin Syndrome, particularly when the medicine is used alongside other agents that affect serotonin levels.

Population and Time-Related Safety Patterns

The official safety information highlights specific considerations for certain groups. Older adults are documented as having increased susceptibility to cardiovascular and anticholinergic effects. For children and adolescents, regulatory notes mandate monitoring for increased risk of suicidal thinking and behavior, especially when treatment begins or dosage changes occur. Many initial CNS and anticholinergic effects are noted to be more frequently observed at the start of treatment or during dose increases.

Safety Restrictions

Regulatory documents specify safety restrictions, including contraindications for use in cases of known hypersensitivity to the drug, immediately following a recent myocardial infarction, and for concurrent use with Monoamine Oxidase Inhibitors (MAOIs).

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory description of an overdose involving Clomipramine (Anafranil SR) highlights the risk of severe, life-threatening effects primarily involving the Central Nervous System and the cardiovascular system.

System Affected	Documented Manifestations
Central Nervous System	Manifestations include somnolence, confusion, agitation, seizures, and progression to stupor or coma.
Cardiovascular System	Severe signs can include tachycardia, significant hypotension, various cardiac arrhythmias, and the potential for cardiac arrest.

Immediate medical attention must be sought for any suspected overdose. The potential for severe systemic events, such as Status Epilepticus or Serotonin Syndrome, mandates prompt contact with emergency services or a Poison Control Center.

Management is strictly symptomatic and supportive, as official documentation confirms that no specific antidote is known. Required procedures include maintaining a patent airway and may involve activated charcoal. Continuous cardiac monitoring via ECG and observation for up to 48 to 72 hours are noted requirements, particularly given the sustained-release nature of the formulation and the risk of delayed peak toxicity. Specific population considerations note increased susceptibility to severe toxicity in both elderly and pediatric patients.

Therapeutic Uses of Anafranil SR

What Anafranil SR Treats: Main Uses and Benefits

The sustained-release formulation of Clomipramine is commonly used to provide supportive therapeutic benefits across specific clinical domains where challenging mental and emotional symptoms cause functional disruption and distress. Its core purpose is focused on the treatment of several key symptomatic areas.

The medicine is relevant in conditions characterized by chronic, persistent emotional distress and affective instability, including Obsessive-Compulsive Disorder (OCD), certain major depressive states, recurrent episodes of intense anxiety and panic, and the specialized support for managing cataplexy episodes associated with narcolepsy.

It may assist in managing the intensity and frequency of persistent, unwanted thoughts and the urge to perform time-consuming, repetitive behaviors. In these scenarios, the medication offers symptomatic relief that may assist with maintaining functional stability during difficult manifestations.

“This medication may be used to moderate distressing manifestations and support general emotional balance during periods of heightened symptoms.”

Quick Fact: Support for Repetitive Symptoms

Anafranil SR is commonly used when symptoms cluster into patterns that create noticeable functional strain, applied in addressing both intrusive obsessions and ritualistic compulsions to help ease the overall symptom burden.

Eligibility and Restrictions for Use

Eligibility for Anafranil SR (Clomipramine Hydrochloride) is strictly defined by regulatory criteria regarding patient population and pre-existing conditions.

Absolute Contraindications

The medicine is strictly contraindicated and must not be used by patients with a known hypersensitivity to Clomipramine or other tricyclic antidepressants. Use is also prohibited during the acute recovery period following a myocardial infarction and in patients diagnosed with congenital long QT syndrome or other severe cardiac arrhythmias. A contraindication also applies in cases of severe liver disease, as documented in certain regulatory monographs.

Age-Group Eligibility and Restrictions

Use is established for the adult population. In the pediatric population, eligibility is restricted to children 10 years of age and older only for the treatment of Obsessive-Compulsive Disorder (OCD); use for other indications is not recommended under 18 years. Geriatric patients must use the medicine under special caution due to altered drug clearance, necessitating lower initial doses.

Conditional Use and Special Populations

Use is generally not recommended for women who are pregnant or breastfeeding, with administration restricted to cases where the benefit outweighs the risk. Special caution is required for individuals with a history of convulsive disorders, narrow-angle glaucoma, or existing severe renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Anafranil SR (Clomipramine Hydrochloride) is governed by officially documented pharmacokinetic and pharmacodynamic effects, primarily concerning metabolic interference and additive risks, as outlined in government regulatory labeling.

Formally Documented Restrictions

Co-administration with several substance classes is subject to regulatory constraint:

Classification	Interacting Entity	Constraint Status
Contraindicated Combinations	Monoamine Oxidase Inhibitors (MAOIs), Linezolid, Intravenous Methylene Blue	Officially Prohibited
Timing Requirements	MAOIs, Fluoxetine	Mandatory Washout Periods

Pharmacokinetic and Pharmacodynamic Interactions

Drug-drug interactions are classified by their resulting outcome on systemic exposure or biological effect:

Metabolic Interactions: Substances that inhibit the CYP2D6 enzyme, such as Fluvoxamine or Fluoxetine, are documented to significantly increase the plasma concentrations of clomipramine and its active metabolite. Hepatic enzyme inducers, conversely, may reduce plasma levels.
Pharmacodynamic Risks: Co-administration with other serotonergic drugs (e.g., Lithium, Tramadol, St. John's Wort) increases the officially noted risk of Serotonin Syndrome. The combination with drugs that prolong the QTc interval is restricted due to the documented risk of additive cardiac effects.
Substance Interactions: Official documents note that Alcohol may alter the effects of clomipramine and increase CNS depressant side effects. Changes in Tobacco/Nicotine use may require changes to the dosing regimen.

Population-Specific Notes

The regulatory profile specifies that CYP2D6 Poor Metabolizers exhibit higher steady-state plasma concentrations of clomipramine, and Elderly Patients (over 65 years) also demonstrate higher exposure than younger adults.

Mechanism of Action

How Anafranil SR Works

The mechanism of action is defined by a dual inhibition of key neurotransmitter transporters and the resulting, slow cellular adaptation within the Central Nervous System (CNS).

Dual Blockade of Neurotransmitter Reuptake

The active component, Clomipramine, and its primary metabolite, Desmethylclomipramine, work together to inhibit the reuptake of both Serotonin ( 5-HT) and Norepinephrine ( NE) by blocking their respective transporters ( SERT and NET). This rapidly elevates the concentration of both signaling molecules in the synaptic cleft, initiating the process of modulation of monoamine activity.

Delayed Adaptation of Neural Circuitry

The persistent, high levels of 5-HT and NE force the postsynaptic receptors and autoreceptors to undergo slow structural changes, such as desensitization and down-regulation. This adaptive response shifts the functional equilibrium of the neuronal circuits, a process of neuroplasticity that is necessary for the sustained change in physiological modulation, and is associated with the characteristic delay between initial molecular action and observable effect.

Non-Selective Physiological Constraint

The drug's molecular structure causes an unavoidable, secondary antagonism at several other receptor sites, including Histamine H1 and Muscarinic Acetylcholine receptors ( M1). These non-selective interactions modulate the autonomic and histaminergic systems, placing an inherent physiological constraint on the extent of the primary mechanistic action.

Dosage and Administration Information

How to Use Anafranil SR: Administration Guidelines

Anafranil SR (Clomipramine Hydrochloride sustained-release) is intended for oral administration. The prolonged-release tablets are designed to deliver the medicine slowly and must be swallowed whole without being chewed, crushed, or cut to maintain the correct release profile.

Dosing and Scheduling

Administration typically begins with a low daily starting dose, which is then progressively increased over a period of time, a process known as titration. The daily dosage is adjusted by the prescribing professional based on individual factors and should not exceed the established maximum daily dose of 250 mg for adults.

During the initial titration period, the dose may be administered in divided doses, often taken with meals to promote tolerability. For maintenance therapy, the total daily amount is generally consolidated into a single dose and is often taken at bedtime (qHS). This timing is a structured part of the use protocol.

Population-Specific Use Rules

Population	Administration Rule
Older Adults (Geriatric)	Must begin with a lower initial dose (e.g., 10 mg daily) and use a lower target maintenance range.
Pediatric (OCD, age 10 years and older)	The daily dose is capped at 3 mg/kg/day or 200 mg/day, whichever is less.

Cessation of Use

Discontinuing the medicine requires a gradual dose reduction (tapering) over time; abrupt cessation is not an approved procedure following regular use. This tapering process is mandated to properly conclude the usage protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Anafranil SR

Evidence for Use in Obsessive-Compulsive Disorder (OCD)

Research primarily examined OCD. Studies examined changes in symptom intensity using standardized rating instruments designed to measure obsessive and compulsive symptom patterns. The research was evaluated in both adult and pediatric populations over defined time intervals, primarily in the form of short-term, placebo-controlled clinical trials.

Studies reported the measurements recorded in the drug group and the placebo group. The evidence highlights changes measured during the study period related to symptom intensity. Studies also monitored what happened when the medication was discontinued. Research describes that this abrupt stopping of the study drug was associated with recurrence in the observed symptom patterns.

However, follow-up durations were limited in many of the key trials, meaning long-term effects are not fully established. Evidence quality varies across studies, and comparative evidence is lacking against many newer agents that was studied for this condition.

Evidence for Use in Cataplexy Associated with Narcolepsy

The evidence record for this use was studied for conditions involving periods of heightened symptoms like cataplexy associated with narcolepsy. Research explored the frequency and severity of cataplexy attacks. The data was observed in small-scale trials and longer observational settings over defined time intervals.

Studies monitored how symptoms evolved and described patterns in the measured number of attacks during the study period. Observational research examined patterns reported over extended follow-up. This evidence contributes to the broader evidence landscape for this use.

Frequently Asked Questions (FAQ)

Common questions about Anafranil SR (FAQ)

Q: What is the difference between Anafranil SR and regular Anafranil?

Anafranil SR is the sustained-release formulation, meaning it is designed to release the medicine slowly into the body over an extended period. Official product information indicates that this design may help to provide more stable levels of the drug in the bloodstream compared to the immediate-release version, which releases the medicine more quickly.

Q: How long does it typically take to notice the effect of Anafranil SR?

Official information indicates that the therapeutic effect is associated with a slow adaptation process in the brain's nerve circuits. Because of this, there is typically a characteristic delay between the time treatment begins and when observable effects are experienced. The onset of action is described as a change that occurs over time rather than immediately.

Q: Can Anafranil SR interact with commonly used over-the-counter pain relievers?

Regulatory documents advise caution regarding co-administration with other medications that could potentially increase the risk of Serotonin Syndrome or affect heart rhythm (QTc prolongation). While specific common pain relievers are not listed as contraindications, the full interaction profile should be discussed with the prescribing professional.

Q: What kind of mental health conditions besides OCD is Anafranil SR approved for?

Official regulatory documents state that the drug is approved for the treatment of Obsessive-Compulsive Disorder (OCD). In some jurisdictions, it is also approved for the control of cataplexy associated with narcolepsy.

Q: Is Anafranil SR safe for older adults?

Official documentation requires special caution when the drug is administered to older adults. This is because this population may have an increased sensitivity to its cardiovascular and anticholinergic effects. Due to these considerations, the official prescribing information specifies a lower initial dose and a reduced maintenance range.

Q: Is Anafranil SR related to other drugs like Prozac or Zoloft?

Anafranil SR is classified as a Tricyclic Antidepressant (TCA), which is a different class of medicine than drugs like Prozac and Zoloft, which belong to the SSRI class. However, regulatory documents mention that these different classes can interact because they affect how the body metabolizes, or breaks down, the medicine.

Q: What should I do if I experience dry mouth while on this medication?

Dry mouth is listed in official documents as a Very Common side effect. This reaction is related to the drug's effect on the body's autonomic nervous system, specifically its anticholinergic activity. Guidance for managing common adverse effects like dry mouth should be discussed with a healthcare professional.

Q: Can taking Anafranil SR affect my ability to drive or operate machinery?

Regulatory documents warn that the drug can cause central nervous system effects, such as dizziness and somnolence (drowsiness). These effects may result in impaired judgment or reaction time, which can affect a person's ability to safely perform skilled tasks like driving or operating heavy machinery.

Q: Is Anafranil SR generally a long-term treatment?

The official dosing protocol includes a maintenance phase of treatment, which supports its use in long-term therapeutic management. However, official research reports note that clinical studies often had limited follow-up duration, meaning the full scope of long-term effects is not completely established by those initial trials.

Q: What are the main reasons someone might need to stop taking Anafranil SR?

Reasons for discontinuation, determined by a prescribing professional, include the development of a serious adverse reaction (such as seizures or severe cardiac arrhythmias) or the presence of a new contraindication. It may also be stopped if it is determined that the patient is not receiving therapeutic benefit from the medicine.

Q: Can Anafranil SR be used by people with kidney problems?

Regulatory documents indicate that the presence of severe renal impairment (kidney problems) requires special caution during the use of this medicine. This is because kidney function can impact how the drug is cleared from the body, and this effect on drug exposure is a factor officially considered by prescribers.

Q: Can I take Anafranil SR if I am also taking medication for blood pressure?

Caution is officially advised regarding co-administration with other drugs, including those that affect blood pressure. Specifically, regulatory documents warn about agents that can cause postural hypotension (dizziness when standing up) or affect heart rhythm. The need for a professional review of all interacting medications is noted in official documentation.

Q: Will I experience withdrawal symptoms if I suddenly stop Anafranil SR?

Official instructions mandate that a gradual dose reduction (tapering) is necessary when discontinuing the medicine. Abrupt cessation is not an approved procedure and may be associated with various adverse effects and the recurrence of the symptoms being treated.

Q: Does Anafranil SR affect sleep patterns?

The drug can cause somnolence (drowsiness) as a Very Common side effect, according to official documents. Due to this known effect on wakefulness, the standard dosing protocol often specifies taking the entire daily dose at bedtime.

Q: Is it safe to switch from another antidepressant to Anafranil SR?

Switching from certain other medications, particularly MAOIs and some other serotonergic drugs, requires a mandated washout period (a drug-free interval). Regulatory documents require this specific timing to be followed to avoid serious interactions such as Serotonin Syndrome.

Q: What types of monitoring are recommended by doctors while on Anafranil SR?

Regulatory documents require monitoring for suicidal thinking and behavior in children and adolescents. Other mandated monitoring can include assessment of blood pressure, cardiac function (ECG), and checks of plasma drug concentrations in the blood.

Q: Does Anafranil SR have a potential for dependence or addiction?

While the terms dependence or addiction are often not explicitly used in this context, official instructions mandate a gradual dose reduction (tapering) procedure upon discontinuing the drug. This is required to manage discontinuation-related effects, as noted in the regulatory documents.

Q: Is it true that Anafranil SR can cause changes in sexual function?

Yes, official regulatory documents list adverse effects related to the reproductive system. Documented changes in libido (sex drive), erectile function, and ejaculation are cited as common side effects.

Q: Does Anafranil SR have a Black Box Warning?

Yes, the FDA label for the drug includes a Boxed Warning. This warning highlights the increased risk of suicidal thinking and behavior in children, adolescents, and young adults during the initial phases of treatment or when the dosage is adjusted.

Q: Is it common for people to report changes in vision while using Anafranil SR?

Official regulatory documents indicate that changes in vision are documented as Common side effects. Specifically, blurred vision and accommodation disorder (difficulty focusing the eye) are listed.

Q: Are there different strengths of Anafranil SR available?

Official drug regulatory documents specify that the sustained-release tablet is available in various strengths. These different strengths reflect the specific concentration of the active ingredient, which allows prescribers to adjust dosing.

Q: What is the official definition of the therapeutic window for this drug?

The concept of a therapeutic window is linked to the monitoring of the plasma concentrations of the active component (clomipramine) and its metabolite in the blood. Official information indicates that these measured concentrations are used to help guide the dosing decisions of health care providers.

Q: Are there any official reports of skin reactions to Anafranil SR?

Yes, official regulatory documents list several types of skin reactions as Common adverse events. These include rash, urticaria (hives), and a documented reaction known as photosensitivity (increased sensitivity to sunlight).

How should Anafranil SR be stored and disposed of?

How to Store and Dispose of Anafranil SR?

The storage and disposal requirements for Anafranil SR (Clomipramine Hydrochloride Sustained-Release Tablet) are strictly defined in official regulatory documents to maintain product stability and ensure safety.

Official Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, between 20 C and 25 C (68 F and 77 F).
Environment	Must be kept away from heat, moisture, and direct light, and strictly kept from freezing.
Packaging	Store in the original container and ensure the bottle is tightly closed.
Child Safety	Mandatory instruction to keep out of the reach of children and store the medicine locked up.

Official Disposal Instructions

Discarding unused or expired Anafranil SR must follow regulated processes. Official instructions mandate that the product must not be disposed of in wastewater or released into the environment. Patients are directed to consult their healthcare provider for specific disposal instructions or utilize drug take-back programs to comply with local and national regulations.

Anafranil SR